



*ASX Limited  
Market Announcements Office*

## **Appointment of Consultant to Assist in Commercialising TPM<sup>®</sup> for the Mass Market**

**09 June 2015, Melbourne:** Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) today announced that it has engaged the services of Dr Steve Meller to assist the Company in partnering its TPM<sup>®</sup> technology with large companies selling into the mass market.

Dr Meller obtained his BSc. (Hons) and PhD from the University of Adelaide before continuing his career in neuroscience research at The University of Adelaide, The University of Iowa and The University of Cincinnati. Thereafter Dr Meller worked for about 20 years in senior global health, innovation and sustainability roles at Procter and Gamble (P&G). He now runs a specialty consulting company based in Silicon Valley with a focus on relationships with both Institutional and Corporate Venture Capital investors. In this capacity he has been an advisor to companies across the globe, including other Australian companies such as ASX-listed OBJ Limited, which in 2014 finalised commercial arrangements with US-based companies P&G and Coty Inc.

Dr Meller will work closely with Phosphagenics to promote its technology to prospective partners, with a focus on the pharmaceutical and consumer health markets.

CEO, Dr Ross Murdoch, said: "We look forward to working with Steve, whose track record speaks for itself. His deep personal global networks, his experience in building and negotiating deals, combined with our technology and the considerable data supporting it, make a strong combination when looking for partners in mass markets."

Dr Meller said: "The amount of data and information collected over more than a decade provides the TPM<sup>®</sup> technology with a strong foundation upon which mass market licensing deals can be made. There is a wide range of potential partners who could be interested in a platform technology that enhances dermal and transdermal delivery of drugs and other molecules."

### **ENDS**

### **Enquiries**

David Segal  
Investor Relations Manager  
Phosphagenics Limited  
+61 3 9565 1103

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

---

### **Phosphagenics Limited**

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168  
PO Box 1415, Clayton South MDC VIC 3169 Australia  
Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151  
[www.phosphagenics.com](http://www.phosphagenics.com) Email: [info@phosphagenics.com](mailto:info@phosphagenics.com)

## **About Phosphagenics**

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM<sup>®</sup> (Targeted Penetration Matrix). TPM<sup>®</sup> is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. Phosphagenics' lead product advancing through clinical trials is an oxycodone patch for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

## **Inherent Risks of Investment in Biotechnology Companies**

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

## **Forward-looking Statements**

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

[www.phosphagenics.com](http://www.phosphagenics.com)